Core products are still pre-clinical/clinical-stage and the website says they are not FDA/CE approved yet, so commercialization depends on trial and regulatory outcomes.
SourceWe make cancer care at home possible.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Irish MedTech startup building technology-enabled oncology care services and wearable devices to reduce chemotherapy side effects and make some cancer care possible at home. Public sources vary on founding year (2018 vs. 2019); the company’s About page says 2019, while other public profiles cite 2018.
Primary product
Lotus Home Infusion platform
Founded
2019
Headquarters
Block 9, Ballybrit, Galway, H91 FW1H, Ireland
Team size
50-60
Work style
Hybrid
Industry
Medical Equipment Manufacturing
Sub-industry
MedTech / oncology supportive care and home infusion
Offices
2 jobs at Luminate
Business model
Stage
Series A
Total raised
$50M
Latest round
Expanded Series A · Jan 2026
Latest amount
$21M
Jan 2026 · ARTIS Ventures and Lachy Groom
Third DTIF grant (reported €6.4M/€6.5M)
Apr 2025 · Irish Government DTIF
Sep 2024 · ARTIS Ventures
Second DTIF grant (€4.4M reported)
Jan 2023 · Irish Government DTIF
Jan 2022 · SciFounders, Elkstone, and Faber
Jan 2022 · Irish Government DTIF
Aug 2021 · Y Combinator
Jan 2019 · Enterprise Ireland
Leadership
CEO and Co-Founder
CCO and Co-Founder
CSO and Co-Founder
Chief Financial Officer
VP R&D and Operations
Emmet Frawley
VP RA/QA
Cathy O'Boyle
Head of Healthcare Services
Investors
Mission-driven, patient-focused, and collaborative; the company describes its teams as engineers, designers, clinicians, and researchers working together to make cancer care more human.
Work style
Hybrid
Compensation
No public salary bands or compensation ranges found.
Pricing
Not publicly disclosed; appears to rely on enterprise/provider and payer partnership contracts rather than public self-serve pricing.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
6.5K
Core products are still pre-clinical/clinical-stage and the website says they are not FDA/CE approved yet, so commercialization depends on trial and regulatory outcomes.
SourceThe Journal Gazette · Jun 2026
Covered Parkview Health’s participation in the Lilac/IMPACT trial and explained the device’s goal of preventing chemotherapy-induced peripheral neuropathy.
GlobeNewswire / ARTIS Ventures · Jan 2026
Announced a $21M expanded Series A, taking total funding to over $50M, with offices in Galway, Chicago, San Antonio, and Omaha and plans to expand home cancer care at 40 partner clinics.
The Irish Times · Jan 2026
Reported the same funding round and said Luminate planned to create 130 jobs.
Silicon Republic · Jan 2026
Covered the $21M raise, 130 planned jobs, and the Lotus home-cancer-care roadmap.
The Irish Times · Jun 2025
Profiled Luminate’s effort to move some cancer care into the home, framing the company’s products and strategy around lower burden and provider-controlled home treatment.